^
    5d
    Dual-targeted approaches in cancer therapy: integrating siRNA and chemotherapy for improved outcomes. (PubMed, 3 Biotech)
    Early clinical candidates, such as EZN-3042 and ALN-VSP, achieved target engagement and biological activity, while limitations included variable tumour uptake, dose-limiting toxicities, and complex pharmacokinetic behaviour. Translation to clinical practice will depend on optimised delivery platforms, reproducible pharmacokinetic/pharmacodynamic synchronisation, and rigorous evaluation of safety and off-target effects. Overall, current evidence highlights substantial potential for siRNA-drug co-delivery while emphasizing key challenges to overcome in achieving durable clinically meaningful outcomes.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • MUC1 (Mucin 1) • BIRC5 (Baculoviral IAP repeat containing 5)
    8d
    NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Mar 2026 --> Jun 2026
    Trial completion date
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    28d
    Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (clinicaltrials.gov)
    P2, N=60, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting
    Enrollment open
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    1m
    NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2025 --> Mar 2026
    Trial completion date
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    3ms
    Triplet RNA Lipid Nanoparticles for Locoregional Cancer Immunotherapy. (PubMed, Small Sci)
    This study demonstrates the potential of a triplet RNA platform-comprising immunostimulatory RNA, mRNA, and siRNA, delivered via a single versatile LNP. The data support development of pIpC-LNPs as potent intratumoral therapeutics and highlight several potential synergistic targets.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • TNFSF4 (TNF Superfamily Member 4)
    3ms
    Itaconate-Related Gene Signatures as Prognostic Markers in Colon Cancer: Insights From Transcriptomic and Spatial Analysis. (PubMed, Hum Mutat)
    Drug sensitivity analysis identified four potentially effective drugs, such as sepantronium bromide, which had better effects on high-risk patients. This study provides a theoretical basis and new targets for precise prognosis and stratified treatment of colon cancer.
    Journal • Tumor mutational burden • Gene Signature • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD36 (thrombospondin receptor) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    sepantronium bromide (PC-002)
    4ms
    Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (clinicaltrials.gov)
    P2, N=60, Suspended, Roswell Park Cancer Institute | Not yet recruiting --> Suspended
    Trial suspension
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    4ms
    From bioinformatics to clinical translation: BIRC5 as a pivotal diagnostic biomarker and therapeutic target for NAFLD-driven HCC. (PubMed, Cell Biol Toxicol)
    This study proposes BIRC5 as a therapeutic target and diagnostic biomarker, offering perspectives for HCC diagnosis and treatment of HCC. These results underscore the importance of BIRC5 in halting NAFLD-HCC progression and provide valuable insights for future clinical applications.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
    |
    sepantronium bromide (PC-002)
    4ms
    Strategic trimodal therapy enhances radiation-induced abscopal response in renal cancer. (PubMed, J Transl Med)
    This study presents a novel and effective strategy to induce the abscopal effect through a synergistic combination of targeted drug delivery, radiotherapy, and immunotherapy. The approach offers strong translational potential for improving radioimmunotherapy outcomes in renal and potentially other immunogenic cancers.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • IL2 (Interleukin 2)
    |
    everolimus • sepantronium bromide (PC-002)
    5ms
    Mapping the Progression of Therapy-Induced Senescence to Therapy Tolerance: An Evolutionarily Conserved Mechanism for Optimizing Cancer Treatment with Senotherapeutics. (PubMed, ACS Pharmacol Transl Sci)
    However, this was most effective within a specific time window after TIS induction. We suggest that the timely use of senotherapeutics could improve the effectiveness of anticancer drugs in clinical settings.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    sepantronium bromide (PC-002)
    5ms
    TACTOPS: TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=37, Completed, Baylor College of Medicine | Trial completion date: May 2027 --> Jul 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date